ライフサイエンスコーパス: clavulanic acid

1 zidime) and beta-lactamase inhibitors (e.g., clavulanic acid).

2 ased inactivators tazobactam, sulbactam, and clavulanic acid.

3 ctamase detectable only after induction with clavulanic acid.

4 ases by the similar inhibitors sulbactam and clavulanic acid.

5 biosynthesis of the beta-lactamase inhibitor clavulanic acid.

6 production of the beta-lactamase inhibitor, clavulanic acid.

7 oxacin (750 mg twice daily) plus amoxicillin/clavulanic acid (1,000 mg twice daily).

8 ne compared with the MIC of ceftazidime with clavulanic acid (2 micrograms/ml) to facilitate the reco

9 tis and who received 2 g of amoxicillin plus clavulanic acid 3 times a day while in the hospital befo

10 Antibiotic disks with and without clavulanic acid, 3-aminophenylboronic acid, or EDTA were

11 irical systemic antibiotics (amoxicillin and clavulanic acid, 375 mg, to be taken 3 times a day for 1

12 imum of 5 days, after which oral amoxicillin/clavulanic acid (875/125 mg every 12 h) could be given f

13 s ampicillin-sulbactam (A/S) and amoxicillin-clavulanic acid (A/C) for 100 consecutive isolates of Ac

14 ts treated with an active BLBLI (amoxicillin-clavulanic acid [AMC] and piperacillin-tazobactam [PTZ])

15 SHV results in resistance to amoxicillin and clavulanic acid, an important clinical beta-lactam-beta-

16 technical difficulties were solved by using clavulanic acid, an irreversible inhibitor of beta-lacta

17 of S130G and SHV-1 differed by only 17% for clavulanic acid and 40% for tazobactam.

18 -spectrum beta-lactam antibiotic amoxicillin/clavulanic acid and a first-generation cephalosporin cef

19 udy extend the biosynthetic gene cluster for clavulanic acid and attest to the importance of analyzin

20 Clavulanic acid and avibactam are clinically deployed se

21 all cultures were susceptible to amoxicillin-clavulanic acid and gentamicin and 99% (one with interme

22 Although clavulanic acid and penicillin share marked structural s

23 olyl groups that distinguish tazobactam from clavulanic acid and sulbactam, respectively.

24 conclude that tazobactam is superior to both clavulanic acid and sulbactam.

25 0G SHV inhibited with tazobactam, sulbactam, clavulanic acid, and 2'-glutaroxy penem sulfone (SA2-13)

26 evant inhibitors, tazobactam, sulbactam, and clavulanic acid, and SHV beta-lactamase (EC 3.5.2.6) hav

27 mase crystals are soaked in 5 mM tazobactam, clavulanic acid, and sulbactam solutions, respectively.

28 lations at 10, 22, and 29 min for sulbactam, clavulanic acid, and tazobactam, respectively.

29 activation by the beta-lactamase inhibitors, clavulanic acid, and tazobactam.

30 nd the inhibitors tazobactam, sulbactam, and clavulanic acid are followed in single crystals of the e

31 Tazobactam, sulbactam, and clavulanic acid are the only beta-lactamase inhibitors i

32 urrently employed in medical practice (e.g., clavulanic acid) are significantly more effective agains

33 ta-lactams, and the beta-lactamase inhibitor clavulanic acid as well as resistance to tetracycline, s

34 orf11 (fd), and orf12, that are required for clavulanic acid biosynthesis as indicated by gene replac

35 treptomyces clavuligerus were sufficient for clavulanic acid biosynthesis, because they allowed produ

36 ly demonstrated to catalyze an early step in clavulanic acid biosynthesis, the ATP/Mg(2+)-dependent i

37 m synthetase (beta-LS), which is involved in clavulanic acid biosynthesis.

38 The orf6 gene of the clavulanic acid biosynthetic gene cluster in S. clavulig

39 the beta-lactamase inhibitors sulbactam and clavulanic acid bound to the deacylation-deficient E166A

40 Based on growth inhibition by clavulanic acid by disk and MIC test methods, 18 (9.5%)

41 ESBL screen test) were further tested for a clavulanic acid (CA) effect by BMD and the disk diffusio

42 Initially, 117 (84%) isolates demonstrated a clavulanic acid (CA) effect by disk diffusion (i.e., an

43 y >/=3 doubling dilutions in the presence of clavulanic acid (CA) or the disk diffusion zone diameter

44 The levels of enamine from tazobactam and clavulanic acid can be increased by increasing the conce

45 t, while results for ampicillin, amoxicillin-clavulanic acid, cefdinir, cefixime, ceftriaxone, and cl

46 Ceftazidime disks with and without clavulanic acid (CLAV) were also tested to confirm exten

47 esponses have been reported with amoxicillin/clavulanic acid, clindamycin, metronidazole, and the com

48 ted directly downstream of orf9 (cad) in the clavulanic acid cluster.

49 iate selective hypersensitivity reactions to clavulanic acid (CLV) and amoxicillin (AX), probably due

50 y > 2 log2 dilution steps in the presence of clavulanic acid) defined a group of 92 probable ESBL-pos

51 ostoperative treatment with amoxicillin plus clavulanic acid did not result in a greater incidence of

52 rger population of enamine than sulbactam or clavulanic acid does and that tazobactam's intermediate

53 fect the amount of trans-enamine formed with clavulanic acid during the critical early time period of

54 ons (microg/ml) and IC(50) concentrations to clavulanic acid for the Met69Ile, Leu, and Val substitut

55 the use of either norfloxacin or amoxicillin-clavulanic acid in the treatment of small bowel overgrow

56 d susceptibility to coamoxiclav (amoxicillin-clavulanic acid) induced DILI.

57 We conclude that the clavulanic acid inhibition of the S130G beta-lactamase m

58 Band broadening in the sulbactam and clavulanic acid inter-mediates reflected a heterogeneous

59 the Raman and x-ray data indicated that the clavulanic acid intermediate is decarboxylated.

60 Clavulanic acid is a potent inhibitor of beta-lactamase

61 Clavulanic acid is a potent inhibitor of beta-lactamases

62 Clavulanic acid is a potent mechanism-based inhibitor of

63 Clavulanic acid is a widely used beta-lactamase inhibito

64 nicillin N, the critical beta-lactam ring of clavulanic acid is demonstrated to form by intramolecula

65 The clinically used beta-lactamase inhibitor clavulanic acid is produced by fermentation of Streptomy

66 -lactamase inhibitors such as tazobactam and clavulanic acid is the expression of variant beta-lactam

67 ble agreement was also found for amoxicillin-clavulanic acid, linezolid, minocycline, and tobramycin.

68 amycin, piperacillin-tazobactam, ticarcillin-clavulanic acid, metronidazole, cefotetan, ampicillin, a

69 co-amoxiclav (250 mg amoxicillin plus 125 mg clavulanic acid; n=1212), both (n=1192), or placebo (n=1

70 co-amoxiclav (250 mg amoxicillin and 125 mg clavulanic acid; n=1550), both (n=1565), or placebo (n=1

71 r, AmpC beta-lactamases are not inhibited by clavulanic acid or other similar compounds.

72 bat these enzymes, agents that inhibit (e.g. clavulanic acid) or evade (e.g. aztreonam) beta-lactamas

73 up B showed higher resistance to amoxicillin-clavulanic acid (P = .03), trimethoprim-sulfamethoxazole

74 es clavuligerus resulted in complete loss of clavulanic acid production and the accumulation of N2-(c

75 ting revealed that ampicillin and ampicillin/clavulanic acid resistance was observed only for the S13

76 Unfortunately, the emergence of clavulanic acid-resistant variants of TEM-1 and SHV-1 be

77 onstant for the preacylation complex, KI, of clavulanic acid (SHV-1, 0.14 microm; S130G, 46.5 microm)

78 With clavulanic acid, slightly smaller amounts of enamine are

79 Comparative inhibitory activities of clavulanic acid, sulbactam, and tazobactam against clini

80 m the CTX-M-9 S130G variant that reacts with clavulanic acid, sulbactam, and tazobactam in solution,

81 can be inhibited by the clinical inhibitors (clavulanic acid, sulbactam, and tazobactam), but the pre

82 he expected product of the beta-LS, restored clavulanic acid synthesis.

83 bserved in children treated with ticarcillin-clavulanic acid (T/C), we conducted a study to determine

84 nd ribitol and susceptibility to amoxicillin-clavulanic acid, the 58 isolates were separable into fou

85 The first committed biosynthetic step toward clavulanic acid, the clinically important beta-lactamase

86 For tazobactam and clavulanic acid, the correctly oriented encounter comple

87 ligands, such as tazobactam, sulbactam, and clavulanic acid, the positioning of the lactam ring in t

88 Clavulanic acid, the therapeutically important inhibitor

89 resistance in S. maltophilia because, unlike clavulanic acid, they do not induce L1 production.

90 ns tested in combination with 4 microg/mL of clavulanic acid was used to confirm ESBL status.

91 s much enamine intermediate as sulbactam and clavulanic acid, which correlates with its superior perf

92 acillin and the combination of oxacillin and clavulanic acid with the Vitek GPS-SA card, the referenc